Tonix Pharmaceuticals stock halted ahead of FDA approval news
lemaitre vascular inc (NASDAQ:LMAT) director John A. Roush sold 7,490 shares of common stock on August 8 and August 11, at prices ranging from $91.8181 to $93.4872, totaling approximately $695,014.
According to a Form 4 filing with the Securities and Exchange Commission, the transactions occurred in multiple sales. On August 8, Roush sold 939 shares at a weighted average price of $93.4872. On August 11, he sold 4,987 shares at a weighted average price of $92.783 and 1,574 shares at a weighted average price of $91.8181.
On the same dates, Roush exercised options to acquire a total of 7,490 shares of Lemaitre Vascular common stock at a price of $37.29, for a total value of $279,675. These options were fully vested and exercisable since December 2, 2020, and expire on December 2, 2025.
In other recent news, LeMaitre Vascular reported strong financial results for the second quarter of 2025, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $0.60, beating the forecasted $0.57. Revenue for the quarter reached $64.2 million, exceeding both Cantor Fitzgerald’s estimate of $62.3 million and the FactSet consensus of $62.5 million. This represents a 15% year-over-year growth, all of which was organic. Cantor Fitzgerald maintained its Neutral rating on the company with a price target of $95.00 following these results. The firm’s positive financial performance indicates robust growth and effective management strategies. These recent developments highlight LeMaitre Vascular’s ability to outperform market expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.